

Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature

Silvia S. Martins, MD, PhD, Laura Sampson, BA, Magdalena Cerdá, MPH, DrPH, and Sandro Galea, MD, MPH, DrPH

Background. Drug overdose is an important, yet an inadequately understood, public health problem. Global attention to unintentional drug overdose has been limited by comparison with the scope of the problem. There has been a substantial increase in drug overdose incidence and prevalence in several countries worldwide over the past decade, contributing to both increased costs and mortality.

Objectives. The aim of this study was to systematically synthesize the peer-reviewed literature to document the global epidemiological profile of unintentional drug overdoses and the prevalence, time trends, mortality rates, and correlates of drug overdoses. We searched different combinations of Medical Subject Headings (MeSH) terms in PubMed for articles published from 1980 until July 2013, and we organized these results in tabular spreadsheets and compared them. We restricted the search to English-language articles that deal with unintentional overdose, focusing on 1 or more of the following key constructs: prevalence, time trends, mortality rates, and correlates. The term “overdose” as a MeSH major topic yielded 1076 publications. In addition, we searched the following combinations of non-major MeSH terms: “street drugs” and “overdose” yielded 180, “death” and “overdose” yielded 114, and “poisoning” and “drug users” yielded 17. There was some overlap among the searches. Based on the search and inclusion and exclusion criteria, we selected a total of 169 relevant articles for this article based on a close review of abstracts.

Results. We found wide variability in lifetime prevalence of experiencing a nonfatal overdose or witnessing an overdose, and in mortality rates attributable to overdose. Lifetime prevalence of witnessed overdose among drug users ($n = 17$ samples) ranged from 50% to 96%, with a mean of 73.3%, a median of 70%, and a standard deviation of 14.1%. Lifetime prevalence of drug users personally experiencing a nonfatal overdose ($n = 27$ samples), ranged from 16.6% to 68.0% with

a mean of 45.4%, a median of 47%, and a standard deviation of 14.4%. Population-based crude overdose mortality rates ($n = 28$ samples) ranged from 0.04 to 46.6 per 100 000 person-years. This range is likely attributable to the diversity in regions, time periods, and samples. Most studies on longitudinal trends of overdose death rates or overdose-related hospitalization rates showed increases in overdose death rates and in overdose-related hospitalization rates across time, which have led to peaks in these rates at the present time. An overall trend of increasing deaths from prescription opioid use and decreasing deaths from illicit drug use in the past several years has been noted across most of the literature. With the increase in prescription opioid overdose deaths, drug overdose is not just an urban problem: rural areas have seen an important increase in overdose deaths. Lastly, cocaine, prescription opioids, and heroin are the drugs most commonly associated with unintentional drug overdoses worldwide and the demographic and psychiatric correlates associated with unintentional drug overdoses are similar globally.

Conclusions. There is a need to invest in research to understand the distinct determinants of prescription drug overdose worldwide. Several other countries need to collect in a systematic and continuous fashion such data on sales of prescription opioids and other prescription drugs, nonmedical use of prescription drugs, and hospitalization secondary to overdoses on prescription drugs. The sparse evidence on the environmental determinants of overdose suggests a need for research that will inform the types of environmental interventions we can use to prevent drug overdose. Methodological issues for future studies include enhancing data collection methods on unintentional fatal and nonfatal overdoses, and collecting more detailed information on drug use history, source of drug use (for prescription drugs), and demographic and psychiatric history characteristics of the individual who overdosed. (*Am J Public Health*. 2015;105:e29–e49. doi:10.2105/AJPH.2015.302843)

PLAIN-LANGUAGE SUMMARY:

Drug overdose is an important, yet inadequately understood, public health problem. The aim of this study was to systematically summarize the peer-reviewed literature to document the global epidemiological profile of unintentional drug overdoses, and the prevalence, time trends, mortality rates, and correlates

of drug overdoses from 1980 until 2013. We found wide variability in prevalence mortality rates attributable to overdose. Most studies on longitudinal trends of overdose deaths or overdose-related hospitalizations showed increases across time. An overall trend of increasing deaths from prescription opioid use and decreasing deaths from illicit drug

use in the past several years has been noted across most of the literature. With the increase in prescription opioid overdose deaths, drug overdose is not just an urban problem: rural areas have seen an important increase in overdose deaths. Lastly, cocaine, prescription opioids, and heroin are the drugs most commonly associated with unintentional drug

overdoses worldwide and the demographic and psychiatric correlates associated with unintentional drug overdoses are similar globally. Future studies need to collect more detailed information on drug use history, source of drug use (for prescription drugs), and demographic and psychiatric history characteristics of the individual who overdosed.

Worldwide attention to unintentional drug overdose has been limited by comparison with the scope of the problem.¹ There has been a substantial increase in drug overdose mortality in several countries worldwide over the past decade. The mortality rate from drug overdoses tripled in the United States between 1990 and 2006.² In the United States, unintentional overdose deaths among adults aged 25 to 64 years exceeded motor vehicle crash deaths and suicides as a leading cause of injury death from 2008 onward.³ Likewise, unintentional overdose deaths outnumbered motor vehicle crash deaths in Australia in 2011.⁴ In Europe, rates have been stable since 2005, but most European countries also have high overdose rates. For example, overdose rates of more than 20 deaths per million are found in 14 of 30 European countries, and rates of more than 40 deaths per million in 7 countries.⁵

Until recently, drug overdoses were seen as a substance abuse or law enforcement issue and not as a public health problem.¹ However, partly because of the increasing involvement of legal prescription drugs such as prescription opioids in drug overdoses, public health professionals have become more interested in the topic and in diminishing the societal burden posed by unintentional overdoses.¹

Although drug overdose deaths attract much public attention,^{1,6-8} there are substantial consequences of nonfatal overdose, including cardiac and muscular problems, cognitive impairment, renal failure, hearing loss, and injuries sustained during overdose.^{9,10} Health care costs associated with overdose treatment are also substantial. From 1999 to

2008, hospitalization rates for overdoses in the United States increased by 55%, costing about \$737 million in 2008.¹¹ There are little data available on drug overdose hospitalization costs in countries other than the United States.

Drug overdose can be defined as happening when

someone . . . collapses, has blue skin, has convulsions, has difficulty breathing, loses consciousness, cannot be woken up, has a heart attack or dies while using drugs.^{12(p704)}

This definition has been used widely across the literature.¹³⁻¹⁶

Unintentional drug overdoses are unique among causes of morbidity and mortality in 2 respects. First, unintentional overdose deaths are rarely instantaneous and drug users rarely overdose alone. As such, for the most part, overdose deaths are avoidable deaths. For example, those who witness an overdose episode can call for help and apply first aid measures.¹⁶ Opioid overdoses are preventable through the administration of naloxone, which can reverse the effect of opioids and can revive the individual.¹⁶⁻¹⁸ Second, drug overdoses are inevitably and inextricably linked to the surrounding environment, particularly in the centrality of drug availability as a necessary (but insufficient) determinant of overdose.¹⁹⁻²³ Considering these observations that overdose is preventable and linked to surrounding environment, drug overdoses should be of concern to public health, both from the point of view of understanding their determinants and from the point of view of encouraging interventions to mitigate their consequences.

A systematic review of the drug overdose literature can help clarify what we know about

unintentional drug overdoses and areas in which we have gaps in scholarship. Although reviews have been written about overdoses caused by particular types of drugs (e.g., prescription opioids, heroin, methadone),²⁴⁻²⁷ in certain places (e.g., Utah),²⁸ on suicidal versus accidental overdose,²⁹ or on overdoses among recently released prisoners,³⁰ we are not aware of any global review of unintentional drug overdoses with the goal of synthesizing the prevalence, time trends, mortality rates, and correlates of drug overdose worldwide.

METHODS

The potential scope of literature that may be considered of interest to the topic is vast. We conducted a systematic review of publications available in the US National Library of Medicine's PubMed electronic database³¹ in July 2013 by using different combinations of Medical Subject Headings (MeSH) search terms. We restricted the search to English-language articles published between 1980 and July 2013 that deal with unintentional overdose, focusing on 1 or more of the following key constructs: prevalence, time trends, mortality rates, and correlates. The term "overdose" as a MeSH Major Topic yielded 1076 publications. In addition, we searched the following combinations of nonmajor MeSH terms: "street drugs" and "overdose" yielded 180, "death" and "overdose" yielded 114, and "poisoning" and "drug users" yielded 17. There was some overlap among the searches. We did not use "unintentional" as a search term so as not to leave out studies that dealt with both intentional and accidental overdoses. There were no limitations in this original search on type of sample, or location or geography, but we

excluded studies dealing with children, because, although this group is important, we aimed to focus only on studies that reported on unintentional drug overdoses among adults. We included commentaries because of their potential to shed light on potential interventions or trends. In addition, we reviewed reference lists of chosen articles to select additional studies or commentaries.

With these search and inclusion and exclusion criteria, we selected a total of 169 relevant articles for this study through a close review of abstracts (Figure 1). We were interested in articles that reported

1. population-based prevalence measures (46 articles; reported in Table 1),
2. studies that reported percentage of changes over time in trends of overdose (34 articles; Table 2),
3. mortality rates (53 articles; Table 3), and
4. correlates of overdose (summarized in the Results section, but not included in tables because of the lack of common quantitative measures to record these topics).

RESULTS

Table 1 shows prevalence of overdose found in relevant articles, organized by type of drug, sample, and type of prevalence (witnessed vs experienced, fatal vs nonfatal, and time point). Lifetime prevalence of witnessed overdose among drug users (n = 17 samples from 18 articles) ranged from 50% to 96%,^{15-17,32,33,37,39,40,43-45,53,54,57-60,64} with a mean of 73.3%, a median of 70%, and a standard deviation of 14.1%. Although samples differed in demographics, length of drug use, and type of drug involved (e.g.,




FIGURE 1—Flowchart of selection of peer-reviewed articles to document the worldwide epidemiological profile of unintentional drug overdoses.

prescription opioids, cocaine), the lifetime prevalence of witnessing an overdose did not differ greatly between studies conducted in different settings and countries.

Two studies reported lifetime prevalence of witnessing a fatal overdose specifically: 1 found that 4 of 24 drug users attending a general medical practice in inner-city Dublin, Ireland, in 1998 to 1999 had witnessed a fatal overdose⁴⁰; the other reported a 15% prevalence among 763 injection drug users from 16 different cities of the Russian Federation.⁵⁹ Two studies reported past-year prevalence of witnessed fatal or nonfatal overdose: 50% among 973 users aged younger than 30 years who had injected drugs in the previous month in 4 neighborhoods of San Francisco, California,⁵⁸ and 58% of 212 users in Dorset, United Kingdom,

who had injected in the previous 2 months.⁶² One study of drug users aged 18 years or older in New York City (n = 1184) reported past-6-month prevalence of witnessing overdose at 35.2%¹⁶ and 2 samples of injection drug users reported past-3-month prevalence of witnessing overdose at 48.5% and 50%.^{32,55}

Lifetime prevalence of drug users personally experiencing a nonfatal overdose had a considerably wider range across studies (n = 29 samples), varying from 16.6% to 68.0%,^{9,13-16,32,37-44,46-48,50,53,56,58-61,63,64,67-69} with a mean of 45.4%, a median of 47%, and a standard deviation of 14.4%. Past-year prevalence of drug users personally experiencing a nonfatal overdose (n = 14 samples) ranged from 4.0% to 38.0%,^{9,35,36,42,46-50,52,58,62,63,67} with a mean of 18.8%, a median of

16.8%, and a standard deviation of 8.9%. Past-6-month prevalence of drug users personally experiencing a nonfatal overdose ranged from 6.7% to 33% (n = 7 samples),^{19,34,51,61,65,66,70} with a mean of 18.5%, a median of 17%, and a standard deviation of 10.4%. Two studies reported past-3-month prevalence of overdose: one found that 11.9% of drug users had overdosed out of 644 users younger than 30 years in San Francisco who had injected in the past 30 days⁵⁶ and the other found a prevalence of 15.2% among injection drug users, most of whom were homeless or in temporary housing, in Los Angeles, California, in 2006.⁵⁵

Trends

We reviewed articles for overall longitudinal trends of overdose

death rates or overdose-related hospitalization rates (Table 2). Rates of increase for overdose deaths in population samples caused by any substance ranged from a 5.3% average increase per year in the United States from 1979 to 1990 to a 400% increase in both Glasgow, Scotland, between 1991 and 1992, and Vermont between 2001 and 2006.^{6,71-73,75-85}

Between 1974 and 1992 in England and Wales, there was a 1186% increase in lethal self-poisonings from heroin alone.¹⁰¹ In the same location between 2007 and 2008, there was an 8% increase in heroin or morphine deaths among women, and a 20% increase in cocaine deaths among women.⁸⁵ There was a 21.4% decrease in illicit drug overdose deaths in Florida between 2003 and 2009,⁸² and a 43% to 85% decrease among all drug-related deaths in Australia in 2001.⁷⁴ In the Australian study, the reduction is believed to have been driven mainly by a reduction in heroin supply. A 34% decrease in illicit drug overdose deaths was seen in the city of Chicago, Illinois, from 2000 to 2003.⁹⁵ One study reported a 55% increase in hospitalization rates for drug overdoses on all substances among a nationwide sample in the United States from 1999 to 2008.¹¹

An overall trend of increasing deaths from prescription opioid use and decreasing deaths from illicit drug use in the past several years has been noted across most of the literature.^{80-82,89,90,96,97,99,100} With the exception of Australia, which experienced a 60% decrease in opioid deaths between 1990 and 2001,⁹¹ most studies in Table 2 reported increased rates of deaths from opioids.^{2,6,80-82,87,90,92,100} For example, there was a 467.7% increase reported in methadone

TABLE 1—Studies Reporting the Prevalence of Unintentional Drug Overdose Worldwide, 1980–2013

Reference	Type of Drug ^a	Location and Time Period	Sample or Source	Type of Prevalence	Time Point	Prevalence, %
Coffin et al. ¹⁵	All substances	New York, NY, 2001–2004	Street-recruited habitual drug users ^b (n = 772)	Witnessed, both fatal and nonfatal	Lifetime	68.5
Galea et al. ³²	All substances	New York, NY, 2004–2005	Overdose prevention and reversal program through a syringe exchange program—pilot study (n = 25)	Experienced (nonfatal) Experienced (nonfatal)	Lifetime Lifetime	16.6 68.0
Tobin et al. ³³	All substances	Baltimore, MD, 2002–2003	Self-Help in Eliminating Life-Threatening Diseases HIV-prevention study ^c	Witnessed, both fatal and nonfatal	Past 3 mo (of follow-up) Lifetime	83.0 50.0 70.0
Werb et al. ³⁴	All substances	Vancouver, BC, 2005–2006	At-Risk Youth Study (n = 478)	Experienced (nonfatal)	Past 6 mo	11.0
Britton et al. ³⁵	All substances (treatment sample)	11 mid- to large urban areas in the United States	Drug Abuse Treatment Outcomes Study ^d	Experienced (nonfatal)	Past year (after treatment)	3.1
Tracy et al. ¹⁶ , Bohnert et al. ¹⁷	Heroin, crack, and cocaine	Central Harlem and South Bronx, NY, 2001–2004	Targeted street outreach of drug users aged ≥ 18 y (n = 1184)	Witnessed, both fatal and nonfatal	Lifetime	67.3
Bohnert et al. ¹⁴	Heroin, crack, and cocaine	Central Harlem and South Bronx, NY, 2001–2004	Among those who had ever witnessed (n = 672) Analytic sample = 1093	Witnessed, both fatal and nonfatal Experienced (nonfatal)	Past 6 mo Lifetime	35.2 45.0
Galea et al. ³⁶	Heroin, crack, and cocaine	Central Harlem and South Bronx, NY, 2001–2004	Among 928 persons who used cocaine during the past year	Experienced (nonfatal)	Past year	17.0
Lagu et al. ³⁷	Heroin, crack, and cocaine	Providence, RI, 2002–2004	Among 1059 persons who used heroin during the past year 329 study participants ^e	Witnessed, both fatal and nonfatal Experienced (nonfatal)	Lifetime	64.6 34.6
Brådvik et al. ³⁸ Baca and Grant ³⁹	Heroin	Malmö, Sweden, 2003	149 regular heroin users	Experienced (nonfatal)	Lifetime	65.8
	Heroin	Albuquerque, NM, 2002	Recruited from a syringe-exchange program: aged ≥ 18 y, used heroin in past 3 mo (n = 101)	Witnessed, both fatal and nonfatal	Lifetime	94.1
Cullen et al. ⁴⁰	Heroin	Dublin, Ireland, 1998–1999	Questionnaire-based interview of drug users attending an inner city general practice (n = 24) Questionnaire-based interview Questionnaire-based interview	Experienced (nonfatal) Witnessed, both fatal and nonfatal	Lifetime Lifetime	64.4 96.0
Darke et al. ⁴¹	Heroin	Sydney, Australia, 2001–2002	ATOS cohort of 615 heroin users ^f	Witnessed fatal Experienced (nonfatal) Experienced (nonfatal)	Lifetime	17.0 42.0 54.0

Continued

TABLE 1—Continued

Darke et al. ⁴²	Heroin	Southwestern Sydney, Australia, 1995–1996	112 heroin users recruited through needle and syringe exchanges; had used heroin in preceding 24 hr	Experienced (nontatal)	Lifetime	53.0
Kerr et al. ⁴³ , Kerr et al. ⁴⁴	Heroin	Melbourne, Australia, 2007	99 injecting heroin users were recruited and interviewed at needle and syringe programs	Witnessed, both fatal and nontatal	Past year Lifetime	16.4 84.0
Darke et al. ⁹	Heroin	New South Wales, Australia, 2001–2005	Cohort study of 387 heroin users: ATOS	Experienced (nontatal) Experienced (nontatal)	Lifetime Lifetime (at baseline)	61.0 55.0
Darke et al. ⁴⁵	Heroin	Sydney, Australia, 1994	329 heroin users	Witnessed, both fatal and nontatal	Past year (at baseline) Past 3 y (of follow-up)	26.6 18.6
Darke et al. ⁴⁶	Heroin	Sydney, Australia, 1994	329 heroin users	Experienced (nontatal)	Lifetime	86.0
Gossop et al. ⁴⁷	Heroin	South London, UK, 1992–1994	Drug Transitions Project: 438 heroin users were contacted and interviewed by privileged-access interviewers	Experienced (nontatal)	Lifetime Past year Lifetime	68.0 29.0 23.0
Seal et al. ⁴⁸	Heroin or “speedballs” (a cocaine and heroin mixture)	San Francisco, CA, 1998–1999	1427 heroin injectors were recruited from 6 inner-city neighborhoods (part of UHS)	Experienced (nontatal)	Past year Lifetime	9.4 48.0
Taylor et al. ⁴⁹	Injected heroin only Injected heroin + other drugs Methadone Buprenorphine Temazepam Cocaine Ecstasy Injection drugs	Glasgow, Scotland, 1993–1994	1018 recruited IDUs	Experienced (nontatal)	Past year Past year	13.0 22.0 32.0 29.0 26.0 31.0 37.0 38.0 42.0
Bluthenthal et al. ⁵⁰		San Francisco, CA, 1997	UHS: 1114 street-recruited, active IDUs in 6 San Francisco Bay Area communities UHS: 1114 street-recruited, active IDUs in 6 San Francisco Bay Area communities	Experienced (nontatal) Experienced (nontatal)	Lifetime Past year	12.3
Seal et al. ⁵¹	Injection drugs	San Francisco, CA, 2001	UHS (n = 487): recruited from street settings in San Francisco and screened for enrollment ⁴⁸	Experienced (nontatal)	Past 6 mo (baseline)	17.0

Continued

TABLE 1—Continued

Jenkins et al. ⁵²	Injection drugs (primarily heroin)	San Francisco, CA, 2002 Seattle, WA, 2009	Seattle and King County ^b (n = 447 clients)	Experienced (nontatal)	Past 6 mo (follow-up) Past year	12.0 16.0
Sherman et al. ⁵³	Injection drugs	Baltimore, MD, 1999–2002	Risk Evaluation and Assessment of Community Health III ^c (n = 309)	Witnessed, both fatal and nontatal	Lifetime	57.0
Pollini et al. ⁵⁴	Injection drugs	Baltimore, MD, 2003–2004	Cross-sectional survey administered to 924 IDUs in ongoing cohort study HRC ^d (n = 66)	Experienced (nontatal)	Lifetime	29.0
Wagner et al. ⁵⁵	Injection drugs	Los Angeles, CA, 2006	UFO (“U Find Out”) Study ^k (n = 644)	Witnessed, both fatal and nontatal	Past 3 mo (at baseline)	15.2
Evans et al. ⁵⁶	Injection drugs	San Francisco, CA, 1997	UHS ^l (n = 82)	Experienced (nontatal)	Lifetime	39.1
Seal et al. ⁵⁷	Injection drugs	San Francisco, CA, 1999–2000	IDUS aged < 30 y ^m (n = 973)	Witnessed, both fatal and nontatal	Past 3 mo (at baseline)	11.9
Davidson et al. ⁵⁸	Injection drugs	San Francisco, CA, 1997–2000		Witnessed, both fatal and nontatal	Lifetime	89.0
Ochoa et al. ¹³	Injection drugs	San Francisco, CA, 1996	Drug users aged 14–29 y ⁿ	Witnessed, both fatal and nontatal	Lifetime	73.0
Sergeev et al. ⁵⁹	Injection drugs	Russian Federation, 2001	Harm Reduction Training Project ^o (n = 763)	Witnessed, both fatal and nontatal	Past year Lifetime	50.0 47.0
Powis et al. ⁶⁰	Injection drugs	London, UK, 1994–1995	312 current IDUs ^p	Witnessed, both fatal and nontatal	Past year	26.8
Fairbairn et al. ¹⁹	Injection drugs	Vancouver, BC, 2003–2005	Vancouver Injection Drug Users Study (n = 551)	Experienced (nontatal)	Lifetime	48.0
Kerr et al. ⁶¹	Injection drugs	Vancouver, BC, 1996–2004	Vancouver Injection Drug Users Study ^q (n = 1587)	Experienced (nontatal)	Past 6 mo (follow-up) Lifetime (at baseline)	6.7 47.0
Bennett and Higgins ⁶²	Injection drugs	Dorset, UK, 1995–1996	Drug users who had injected in the 2 mo before interview (n = 212); multisource sampling	Experienced (nontatal)	Past 6 mo (follow-up) Past year	32.7 30.0
Bergensstorm et al. ⁶³	Opioids	Bac Ninh and Tu Son, Vietnam, 2003	299 out-of-treatment male opioid IDUs aged 18–45 y; community-based cross-sectional survey	Witnessed, both fatal and nontatal Experienced (nontatal)	Lifetime	58.0 43.5
Havens et al. ⁶⁴	Prescription opioids, cocaine, heroin, and methamphetamine	Rural Appalachian Kentucky, year undisclosed	Social Networks Among Appalachian People Study ^r (n = 400)	Witnessed, both fatal and nontatal Experienced (nontatal)	Past year Lifetime	36.1 58.2

Continued

TABLE 1—Continued

Fischer et al. ⁶⁵ , Fischer et al. ⁶⁶	Illicit opioids	Vancouver, BC, Edmonton, AB, Toronto, ON, Montréal, QC, and Québec, QC, 2002	The Interdisciplinary Health Research Team on Illicit Opiate Addiction Research, Treatment, and Policy ^f (n = 651)	Experienced (nonfatal)	Past 6 mo	17.2
Tobin et al. ⁶⁷	Cocaine and opioids	Baltimore, MD, 2000	729 opioid and cocaine users completed a cross-sectional survey	Experienced (nonfatal)	Lifetime	35.0
Man et al. ⁶⁸	Opioids (methadone + diazepam)	Southern England, and Glasgow and Edinburgh, Scotland, 1999–2000	Opioid users interviewed in 4 drug misuse treatment services (n = 135)	Experienced (nonfatal)	Past year Lifetime	4.0 56.0
Silva et al. ⁶⁹	Prescription opioids and tranquilizers	New York, NY, and Los Angeles, CA, 2009–2011	596 participants aged 16–25 y ^g	Experienced (nonfatal)	Lifetime	23.6
Kinner et al. ⁷⁰	Illicit drugs	Vancouver, BC, 1996–2010	Prospective cohort of 2515 community-recruited illicit drug users	Experienced (nonfatal)	Past 6 mo	33.0

Note. ATOS = Australian Treatment Outcome Study; HRC = Homeless Health Care Los Angeles Center for Harm Reduction; IDUs = injection drug users; UHS = Urban Health Study.

^aAll substances = opioid and nonopioid substances, both pharmaceutical and illicit, including alcohol.

^bParticipants were users who had been injecting for at least 1 year, had injected heroin within the past 2 months, and were aged ≥ 18 years.

^cSnapshot of fourth wave (n = 568); recruited through street-based outreach, advertisements, and word of mouth; inclusion criteria were aged ≥ 18 years, having daily contact with drug users, and willingness to conduct HIV prevention outreach.

^dA longitudinal naturalistic multisite study; participants included 2966 patients with ≥ 1 substance abuse disorders.

^eParticipants were recruited for a health service research study on drug users if they (1) were aged 18–70 years; (2) had injected heroin or cocaine during the preceding 30 days, or noninjection heroin or cocaine use at least weekly for the past 6 months; (3) had < 30 of the last 90 days spent in institutional settings including prisons and residential drug treatments or hospitalization; (4) spoke English; (5) denied intent to harm self or others; and (6) had absence of psychosis.

^fThe cohort consisted of entrants to treatment of heroin dependence in opioid maintenance, detoxification, and residential rehabilitation; in addition, a group of heroin users not currently in treatment were recruited from needle and syringe programs in the regional health areas from which treatment entrants were recruited.

^gEligible if they injected heroin > 2 times/wk, reported ≥ 1 heroin overdoses in the past 5 year, and could enroll together with an eligible injection partner who met the same criteria.

^hSites included 2 indoor and 2 outdoor exchanges in Seattle, as well as a mobile exchange in suburban King County, n = 447 clients who reported opioid use since the beginning of the year (between January 2009 and the date the survey was administered in April or May of 2009).

ⁱLongitudinal study of 309 15- to 30-year-old IDUs and non-IDUs who had initiated heroin, cocaine, or crack use within 5 y before study enrollment.

^jIDUs, most of whom were homeless or in temporary housing, aged ≥ 18 y; participants were recruited via street outreach, distribution of advertising leaflets, and 1-on-1 recruitment within the HRC.

^kIDUs aged < 30 years, recruited by peer outreach workers with study invitation cards and flyers, contacts with youth-friendly neighborhood groups and community providers, and word of mouth; had to have self-reported use of injection drugs in the past 30 days.

^lOutreach and word of mouth using targeted sampling methods; eligibility determined by physical evidence of recent injection drug use (“tracks” or multiple vein/puncture sites) or participation in previous cross-sections of data collection (final n = 82 who had experienced an overdose and wanted to participate, out of original 552).

^mIDUs aged < 30 years who had injected in the previous month in 4 neighborhoods of San Francisco; outreach and word of mouth.

ⁿDrug users aged 14–29 years who had injected drugs in the previous 6 months; study participants were recruited and interviewed at 6 needle exchanges and 3 youth outreach sites.

^o763 IDUs from 16 cities of the Russian Federation as part of the Harm Reduction Training Project.

^p312 current IDUs were recruited and interviewed in community settings by a team of privileged-access interviewers.

^qPersons were eligible if they had injected illicit drugs at least once in the previous month and resided in the greater Vancouver region.

^rUsers aged ≥ 18 years, residing in an Appalachian county in Kentucky, and had used ≥ 1 of the following drugs to get high in the previous 30 days: prescription opioids, cocaine, heroin, or methamphetamine.

^sParticipants were recruited by a variety of methods, including dissemination of flyers at user contact points such as needle exchanges, advertisements in community articles, and snowball sampling.

^tInterviewed a sample of 596 16- to 25-year-old patients in Los Angeles and New York who had engaged in misuse of a prescription drug (i.e., opioid, tranquilizer, stimulant, or any combination) ≥ 3 times in the past 90 days.

TABLE 2—Studies Reporting Trends Across Time in Unintentional Overdose Worldwide, 1980–2013

Reference	Type of Drug ^a	Location and Time Period	Sample or Source	Measure	Trend or Change
CDC ⁷¹	All substances	United States, 1990–2001	CDC, National Center for Injury Prevention and Control	Overdose death rate	56% increase
White et al. ¹¹	All substances	United States, 1999–2008	Nationwide inpatient sample ^c	Hospitalization rates	145% average increase (range = 28%–325% [FI = 325%])
Paulozzi et al. ⁷²	All substances	United States, 1990–2003	National Center for Health Statistics: Whites National Center for Health Statistics: African Americans	Drug-induced death rate	55% increase 189% increase 64% increase
Paulozzi et al. ⁷³	All substances	United States, 1999–2004	NVSS	Unintentional and undetermined drug poisoning mortality rates	62.0% increase
Degenhardt et al. ⁷⁴	All substances	New South Wales, Australia, 2001	NVSS, metropolitan counties only NVSS, nonmetropolitan counties only	Drug-related deaths that appeared to be driven by the reduction in heroin supply	51.0% increase 159% increase 43% decrease
Edwards et al. ⁷⁵	All substances	Victoria, Australia, 2001 Vermont, 2006–2009 Vermont, 2009–2010	Medical Examiner's Office	Drug-induced death rate	85% decrease 27.4% increase 16.0% decrease
Wunsch et al. ⁷⁶	All substances	Western Virginia, 1997–2003	Retrospective, population-based review of medical examiner cases	Deaths with a direct or contributing cause of drugs	300% increase
Hammersley et al. ⁷⁷	All substances	Glasgow, Scotland, 1991–1992	The Department of Forensic Medicine and Science Laboratory	Drug-induced death rate	400% increase
Shah et al. ⁷⁸ , Mueller et al. ⁷⁹	All substances	New Mexico, 1990–2005	New Mexico Office of the Medical Investigator	Unintentional drug overdose death numbers and rates	176.8% increase
Paulozzi et al. ⁸⁰	All substances	United States, 1979–1990	NCHS	Unintentional drug poisoning mortality rates	5.3% increase (average per year)
Fingerhut et al. ⁸¹	Opioid analgesics without heroin and cocaine Heroin Cocaine All substances Methadone Heroin Other opioids Cocaine Cannabis	United States, 1990–2002 United States, 1999–2002 United States, 1999–2005	NVSS	Number of poisonings on death certificates Number of poisoning deaths	18.1% increase (average per year); 217.6% total 129.2% increase 12.4% increase 22.8% increase 65.6% increase 467.7% increase 2.4% increase 110% increase 62.5% increase 202.7% increase

Continued

TABLE 2—Continued

CDC ⁸²	All substances Prescription drugs Illicit drugs	Florida, 2003–2009	Florida Medical Examiners Commission	Overdose death rate	47.5% increase 84.2% increase 21.4% decrease
Madden and Shapiro ⁸³	All substances	Vermont, 2001–2006	Retrospective review of the Vermont Office of the Chief Medical Examiner	Overdose deaths	400% increase
Socie et al. ⁸⁴	Methadone	United States, 1996–2006	CDC WISQARS Fatal Injury Reports ^a (WISQARS = Web-Based Injury Statistics Query and Reporting System)	Proportion of overall deaths that include methadone Poisoning death rate	300% increase 74% increase
Wells et al. ⁸⁵	All substances	Ohio, 1996–2006 Ohio, 1999–2008 England and Wales, 2007–2008	National Statistics database	Drug poisoning deaths, men	178% increase 325% increase 8% increase
CDC ^c	Heroin and morphine Cocaine	United States, 1999–2010	CDC	Drug poisoning deaths, women Drug poisoning deaths, women Drug poisoning deaths, women Drug poisoning deaths, women Drug poisoning deaths, men Drug poisoning deaths, women Emergency department visits	17% increase 8% increase 20% increase 151% increase 85% increase 500% increase 560% increase
Wisniewski et al. ⁸⁶	Opioids Oxycodone	United States, 1995–2002	Consolidated from the Drug Abuse Warning Network database ^b		
Cerdá et al. ²	Morphine	New York, NY, 1990–2006	Office of the Chief Medical Examiner of NYC	Overdose death rate	116% increase
CDC ⁸⁷	Hydrocodone	United States, 1999–2009	NVSS	Overdose death rate	160% increase
Hawton et al. ⁸⁸	Prescription analgesics Methadone Coproxamol	England and Wales, 1998–2010	Office for National Statistics	Overdose death rate Number of overdose deaths after withdrawal of coproxamol	700% increase 550% increase 62% decrease (after intervention)
The DAWN Report ⁸⁹ Green et al. ⁹⁰	Prescription drugs Opioids	United States, 2004–2011 Connecticut, 1997–2007	Drug Abuse Warning Network database Connecticut Office of the Chief Medical Examiner	Emergency department visits Absolute number of overdose deaths	232.5% increase 44% increase
Degenhardt et al. ⁹¹	Methadone Opioids	New South Wales, Australia, 1999–2001 2000–2002	Australian Bureau of Statistics, et al. ^f	Overdose deaths with toxicological data Overdose deaths Opioid deaths	80% increase 379% increase 60% decrease
Calcaterra et al. ⁹²	Pharmaceutical opioids	United States, 1999–2009	CDC WONDER Database; 15- to 64-year-old patients	Presentations of opioid overdose to emergency departments Age-adjusted death rate	45% decrease 292.9% increase

Continued

TABLE 2—Continued

Author(s)	Prescription opioids	Intervention ^g	Medication-related overdose deaths following program implementation	14.0% decrease (after intervention)
Cochella et al. ⁹³ , Johnson et al. ⁹⁴	Prescription opioids	Utah, 2007–2008	Medication-related overdose deaths following program implementation	14.0% decrease (after intervention)
Scott et al. ⁹⁵	Illicit opioids	Chicago, IL, 2000–2003	Incidence of fatal overdose	34% decrease
Marshall et al. ⁹⁶ , Wood et al. ⁹⁷	Injection drugs	Vancouver, BC, 2001–2005	Overdose death rates after opening of first medically supervised safe-injection facility	35% decrease (after intervention)
Friedman ⁹⁸	Heroin and fentanyl	Illinois, 2006–2005	Heroin-related calls	63.6% increase
Schwartz et al. ⁹⁹	Heroin	Baltimore, MD, 1995–2002 vs 2003–2009	Average annual heroin overdose deaths (after buprenorphine became available)	37% decrease
Maxwell et al. ¹⁰⁰	Heroin	Chicago, IL, 1996–2000	Opioid overdose deaths	400% increase
		Chicago, IL, 2000–2001	After prevention program started providing naloxone	20% decrease (after intervention)
Neelaman and Farrell ¹⁰¹	Heroin alone	England and Wales, 1974–1992	Lethal self-poisonings (including accidental, suicidal, and unknown)	1186% increase
	Methadone with or without heroin	Office of Population Censuses and Surveys tabulations Office of Population Censuses		823% increase

Note. CDC = Centers for Disease Control and Prevention; NCHS = National Center for Health Statistics; NWSS = National Vital Statistics System; NYC = New York City; WONDER = Wide-Ranging Online Data for Epidemiologic Research.

^aAll substances = opioid and nonopioid substances, both pharmaceutical and illicit, including alcohol.

^bColorado, Delaware, Kentucky, New Mexico, Florida, Massachusetts, North Carolina, Oregon, Washington, Utah, Wisconsin.

^cDesigned to approximate a 20% sample of US community hospitals as defined by the American Hospital Association. Poisoning and nondependent abuse of alcohol and drugs in patients aged 18–24 years.

^dHospital emergency departments, ambulance services, and coroner's systems; treatment entries for heroin dependence compiled by state health departments; numbers of needles and syringes distributed to drug users; and data on arrests for heroin-related incidents and property-related crime incidents compiled by State Police Services.

^eMedical record and toxicology screening data from a nationally representative hospital sample.

^fAustralian Bureau of Statistics and the Division of Analytical Laboratories, Institute of Clinical Pathology and Medical Research, Western Sydney Area Health Service, the Ambulance Service of New South Wales Case Sheet Database, and other emergency department data.

^gPresentations highlighting six recommended prescribing practices were developed and presented to health care workers. Participants were encouraged to utilize the state prescription database and to complete a series of surveys assessing confidence and behavior changes at 0, 1, and 6 months post-presentation. Continuing medical education credits incentivized participation.^{95(p573)}

^hManually screened death certificates from the Illinois Department of Public Health master death files, 1999–2003, and the Chicago Real Time Death Surveillance System, 2003.

deaths in the United States between 1999 and 2005,⁸¹ and a 129.2% increase in deaths from prescription opioids, between 1999 and 2002.⁸⁰

Mortality Rates

Relevant studies that reported either population-based mortality rates attributable to fatal drug overdose, or all-cause and cause-specific death rates among drug users, are presented in Table 3, organized by type of drug, location and time period, and sample. Rates are crude and overdose-related, unless otherwise noted in the table. Rates are reported as number of deaths per 100 000 person-years; we converted original rates from articles that were presented on a different scale accordingly. Mortality rates differed widely depending on the setting and on the source population (i.e., any substance users, injection drug users only, recently released prisoners).

Population-based crude overdose mortality rates (n = 30 samples from 22 articles) ranged from 0.04 to 46.6 per 100 000 person-years.^{5,7,22,41,71,73,76,81,82,84,92,95,107,109–111,121–123,125–127} This range is likely attributable to the diversity in regions, time periods, and samples. The highest rates were generally seen in cities such as Barcelona, Spain,¹¹¹ and Chicago among high-poverty communities,⁹⁵ or in very rural areas such as West Virginia¹²⁵ and Wilkes County, North Carolina,¹²⁷ the latter of which was before an intervention. Population-based adjusted or standardized rates (n = 35 samples from 12 articles) ranged from 0.11 to 253.8,^{2,78,79,92,96,102,103,105,108,111,132,134} the highest rate being that of Vancouver, British Columbia, before the opening of the first medically supervised safe injection facility.⁹⁶

TABLE 3—Studies Reporting Mortality Rates of Unintentional Drug Overdoses Worldwide, 1980–2013

Reference	Type of Drug ^a	Location and Time Period	Sample or Source	Mortality Rate per 100 000 Person-Years, Crude Unless Noted
Duncan ¹⁰²	All substances	United States, 1981 United States, 1982 United States, 1983 United States, 1984 United States, 1985 United States, 1986 United States, 1987 United States, 1988 United States, 1989 United States, 1990 United States, 1991 United States, 2001	Division of Vital Statistics et al. ^b	3.1 (age-adjusted) 3.1 (age-adjusted) 3.1 (age-adjusted) 3.2 (age-adjusted) 3.5 (age-adjusted) 4.0 (age-adjusted) 3.8 (age-adjusted) 4.2 (age-adjusted) 4.1 (age-adjusted) 3.6 (age-adjusted) 3.8 (age-adjusted) 7.8
CDC ⁷¹	All substances	United States, 2001	CDC, National Center for Injury Prevention and Control	7.8
Paulozzi et al. ⁷³	All substances	United States, 2004	NVSS	7.8
Warner et al. ¹⁰³	All substances	United States, 2008	NVSS	9.2 (age-adjusted)
CDC ⁶	All substances	United States, 2010	CDC; female rate	9.8
Merrall et al. ¹⁰⁴	All substances	Scotland, 1996–2000	Scottish Drug Misuse Database cohort ^c	498 (95% CI = 454, 545)
Shah et al. ⁷⁸ ; Mueller et al. ⁷⁹	All substances	Scotland, 2001–2005 New Mexico, 1990–2005	New Mexico Office of the Medical Investigator	357 (95% CI = 334, 381) 10.4 (age-adjusted)
Shah et al. ¹⁰⁵	All substances	New Mexico, 2005–2009	New Mexico Office of the Medical Investigator	17.6 (95% CI = 16.8, 18.5; age-adjusted)
Socie et al. ⁸⁴	All substances	Ohio, 2008	CDC WISQARS Fatal Injury Reports; Ohio Department of Vital Statistics	13.7
Wunsch et al. ⁷⁶	All substances	Metropolitan Virginia, 1997–2003 Metropolitan Virginia, 1997–2003 Rural Virginia, 1997–2003	Office of the Medical Examiner ^d	6.77 (95% CI = 6.12, 7.42) 7.68 (95% CI = 6.16, 9.20) 10.76 (95% CI = 9.67, 11.85)
Farrell and Marsden ¹⁰⁶	All substances	England and Wales, 1998–2003	National sample of prisoners ^e ; men National sample of prisoners ^e ; women	520 (converted) 590 (converted)
EMCDDA ⁵	All substances	European Union, 2010	EMCDDA; population aged 15–64 y	2 (converted)
Marshall et al. ¹⁰⁷	Illicit drugs	British Columbia, 2001–2005	British Columbia Coroners Service ^f	4.38 (95% CI = 4.10, 4.67)
Milloy et al. ¹⁰⁸	Cocaine Illicit drugs	British Columbia, 2001–2005	British Columbia Coroners Service	2.58 4.84 (age-adjusted)
Harlow ¹⁰⁹	Narcotics (heroin, morphine, dilaudid, etc.) Cocaine	Texas, 1976–1987 Texas, 1983–1987	Among those with First Nations Identity Medical examiner or death certificates filed with the Texas Department of Health	13.3 (age-adjusted) 0.13–0.92 0.04–0.09

Continued

TABLE 3—Continued

Galea et al. ²² , Coffin et al. ¹¹⁰	Cocaine, opioids, alcohol	New York, NY, 1990–1998	Office of the Chief Medical Examiner of NYC ^d	7.3–13.3
Torralba et al. ¹¹¹	Cocaine and opioids	Barcelona, Spain, 1989–1993	City residents in the age group 15–49 y; used the Forensic Institute, and the Sistema d'Informacio de Drogues de Barcelona	15.3 (95% CI = 14.1, 16.5; age- and sex-adjusted)
Marzuk et al. ¹¹²	Cocaine and opioids	New York, NY, 1990–1992	Office of the Chief Medical Examiner of NYC and Census data	1.27 (Upper East Side; age-adjusted); 38.76 (Central Harlem; age-adjusted)
Tardiff ¹¹³	Cocaine without opioids	New York, NY, 1990–1992	Office of the Chief Medical Examiner of NYC and Census data	2.86
Cerdà et al. ²	Opioids without cocaine Cocaine and opioids Cocaine	New York, NY, 1993–1995	Office of the Chief Medical Examiner of NYC	2.29 3.42 15.5 (age-adjusted)
Stenbacka et al. ¹¹⁴	Heroin Prescription analgesics Methadone Illicit drugs	New York, NY, 2006 Stockholm, Sweden, 1967–2003	Users with substance abuse problems (n = 1705) ^h UFO (“U Find Out”) Study ⁱ	14.1 (age-adjusted) 2.7 (age-adjusted) 4.4 (age-adjusted) 277 (95% CI = 258, 295; converted; all-cause)
Evans et al. ⁵⁶	Injection drugs	San Francisco, CA, 1997–2007		912 (95% CI = 663, 1253; converted; all-cause)
Vlahov et al. ¹¹⁵ Marshall et al. ⁹⁶	Injection drugs Injection drugs	5 US cities; ^j 1997–2002 Vancouver, Canada, 2001–2003	Collaborative Injection Drug Users Study ^j British Columbia Coroners Service	7.1 253.8 (95% CI = 187.3, 320.3; standardized)
Hickman et al. ¹¹⁶	Injection drugs	2003–2005 Bristol, England, 2005–2006	Respondent driven sampling and local Office for National Statistics mortality files; among drug users	165.1 (108.8, 221.4; standardized) 400 (converted)
Manfredi et al. ¹¹⁷	Injection drugs	Bologna, Northeastern Italy, 1977–2002	Open cohort of 1214 IDUs, mostly heroin addicts, referring to a specialized outpatient center	451.8 (converted)
Miller et al. ¹¹⁸ Wang et al. ¹¹⁹	Injection drugs Injection drugs	Vancouver, BC, 1996–2004 Baltimore, MD, 1988–2001	Vancouver Injection Drug User Study ^k ALIVE cohort study: 1927 actively IDUs HIV seronegative at baseline (308 later HIV seroconverted)	1368 (all-cause) 1390 (converted)
Brette et al. ¹²⁰	Injection drugs	Edinburgh, Scotland, 1986–1994	ALIVE cohort study, but among seronegative drug users HIV-positive patients from the Edinburgh City Hospital cohort records	560 (converted) 1120 (converted)

Continued

TABLE 3—Continued

Calcaterra et al. ⁹²	Heroin	United States, 2007	CDC WONDER Database; 15- to 64-year-old individuals	1.05 (95% CI = 1.00, 1.09)
Darke et al. ⁴¹	Heroin	United States, 2009 Sydney, Australia, 2001–2009	Australian Treatment Outcome Study cohort of 615 heroin users ¹	1.43 (95% CI = 1.38, 1.48) 643 (95% CI = 437, 913; converted)
Davidson et al. ¹²¹	Heroin	San Francisco, CA, 1997–2000	Medical examiner's case files, Census data	14.29
Ruttenber and Luke ¹²²	Heroin	District of Columbia, 1981	Deaths associated with injected street preparations of heroin (population-based)	17.4
Calcaterra et al. ⁹²	Pharmaceutical opioids	United States, 1999	CDC WONDER Database; 15- to 64-year-old patients	1.54 (95% CI = 1.49, 1.60; age-adjusted) 6.05 (95% CI = 5.95, 6.16; age-adjusted)
CDC ⁷	Opioid painkillers	United States, 2009 Washington State, 2006	CDC; health and human services agencies in WA CDC; health and human services agencies in WA, but among only Medicaid-enrolled population	6.4 30.8 (age-adjusted)
Fingerhut et al. ⁸¹	Methadone	United States, 2005	NVSS	1.5
CDC ⁸⁷	Methadone	United States, 2007	NVSS	1.8
CDC ⁴²³	Methadone	United States, 2009	NVSS	1.5
Soyka et al. ¹²⁴	Methadone and buprenorphine	Munich, Germany	2694 opioid-dependent patients in substitution treatment through the COBRA study	1040 (converted; all-cause)
CDC ⁸²	All substances Prescription drugs Illicit drugs	Florida, 2009	Florida Medical Examiners Commission	15.7 13.4 3.4
Hall et al. ¹²⁵	Prescription drugs	West Virginia, 2006	Population-based, observational study ^m	16.2
Niveau et al. ¹²⁶	Opioids	Geneva, Switzerland, 1999	Cantonal Office of Statistics	3.19
Albert et al. ¹²⁷	Opioids	Wilkes County, NC, 2009 North Carolina, 2009	Before Project Lazarus	46.6 11.0
Bird ¹²⁸	Opioids	European Union, ⁿ 1990s	Combination of 6 European cohorts ⁿ	870 (95% CI = 810, 940; converted)
Bargagli et al. ¹²⁹	Opioids	Barcelona, Spain, 1990	Cohorts recruited through EMCDDA protocol	1296 (converted)
		Denmark, 1990		707 (converted)
		Dublin, Ireland, 1990		309 (converted)
		Lisbon, Portugal, 1990		112 (converted)
		London, England, 1990		737 (converted)
		Rome, Italy, 1990		664 (converted)
		Vienna, Austria, 1990		661 (converted)

Continued

TABLE 3—Continued

Clausen et al. ¹³⁰	Opioids	Norway, 1997–2003	3789 opioid-dependent users ^a	2100 (converted) after treatment
Shah et al. ¹³¹	Opioids	England and Wales, 1993–1998	Coroners' files; men	3.7 (converted)
Scott et al. ⁹⁵	Illicit opioids	Chicago, IL, 2002 ^b	Coroners' files; women Illinois master death files, 1999–2003, and Chicago Real Time Death Surveillance System 2003 ^b	0.94 (converted) 33.0–35.0
Morgan et al. ¹³²	Antidepressants	England and Wales, 1993	Coroners' files	0.9 (converted; age-adjusted)
Rocchi et al. ¹³³	Illicit drugs	England and Wales, 2002 Italy, 1984–2000	Direzione Centrale per i Servizi Antidroga of the Italian Ministry of the Interior; men aged 15–44 y Direzione Centrale per i Servizi Antidroga of the Italian Ministry of the Interior; women aged 15–44 y Provincial coroners' data (all standardized)	0.7 (converted; age-adjusted) 6.6 (range = 1.6–11.3) avg per year 0.7 (range = 0.3–1.1) avg per year
Fischer et al. ¹³⁴	Fentanyl	Ontario, 2009		0.44
	Hydromorphone	British Columbia, 2009		0.11
	Morphine	Ontario, 2009		0.24
	Oxycodone	British Columbia, 2009		0.45
		Ontario, 2009		0.55
		British Columbia, 2009		2.94
		Ontario, 2009		1.09
		British Columbia, 2009		0.70

Note. ALIVE = AIDS Linked to the Intravenous Experience; CDC = Centers for Disease Control and Prevention; CI = confidence interval; COBRA = Cost-Benefit and Risk Appraisal of Substitution Treatments study; EMCDDA = European Monitoring Centre for Drugs and Drug Addiction; IDU = injecting drug user; NVSS = National Vital Statistics System; NYC = New York City; WISQARS = Web-Based Injury Statistics Query and Reporting System; WONDER = Wide-Ranging Online Data for Epidemiologic Research.

^aAll substances = opioid and nonopioid substances; both pharmaceutical and illicit, including alcohol.

^bDivision of Vital Statistics of the US Public Health Service, death certificates, and Drug Enforcement Administration's annual budget.

^cScottish Drug Misuse Database cohort (treatment sample), matched with General Register Office for Scotland.

^dRetrospective, population-based review of medical examiner cases in the Office of the Medical Examiner.

^eNational sample of 48 771 sentenced prisoners released during 1998–2000 with all recorded deaths included to November 2003.

^fAll unnatural, unexpected, or unattended deaths in the province (n = 904).

^gAll cases of fatal accidental drug overdose occurring in individuals aged 15–64 years.

^hUsers were identified through records in Stockholm in 1967; these individuals were followed in registers recording mortality and cause of death and in patient care stays until 2003.

ⁱUFO ("U Find Out") Study comprised 644 injection drug users aged < 30 y, recruited by peer outreach workers with study invitation cards and flyers, contacts with youth-friendly neighborhood groups and community providers, and word of mouth; had to have self-reported use of injection drugs in the past 30 days.

^jCollaborative Injection Drug Users Study comprised community-based, recent onset (< 5 y) injection drug users aged 18–35 years (n = 2089) from 5 US cities: Baltimore, MD; Chicago, IL; Los Angeles, CA; New Orleans, LA; and New York, NY.

^kSelf-referral and street outreach from the Downtown Eastside, one of Vancouver's poorest neighborhoods: injection drug users aged 14–29 y (n = 572).

^lAustralian Treatment Outcome Study cohort consists of entrants to treatment of heroin dependence in opioid maintenance, detoxification, and residential rehabilitation; in addition, a group of heroin users not currently in treatment were recruited from needle and syringe programs in the regional health areas from which treatment entrants were recruited.

^mPopulation-based (all state residents who died of unintentional pharmaceutical overdoses), observational study using data from medical examiner, prescription drug monitoring program, and opioid treatment program records.

ⁿCombination of 6 European cohorts who were recruited according to a common EMCDDA protocol from drug treatment agencies in Barcelona, Spain; Denmark, Dublin, Ireland; Lisbon, Portugal; Rome, Italy; and Vienna, Austria.

^o3789 opioid-dependent users who applied for and were accepted for opioid maintenance therapy (cross-linked with the Norwegian death register).

^pManually screened death certificates from the Illinois Department of Public Health master death files, 1999–2003, and the Chicago Real Time Death Surveillance System 2003. These communities' average poverty rate is 43%, 2 times that of the rest of the city.

Several studies reported on overdose mortality rates stratified by gender. Female-specific population-based overdose mortality rates reported included 9.8 in the United States, 0.94 in England and Wales, 0.7 in Italy, and 590 among recently released female prisoners.^{6,106,131,133} Male rates were 3.7 in England and Wales, 6.6 in Italy, and 520 among recently released male prisoners.^{106,131,133} Generally, death rates were higher among men than women, with the exception of recently released prisoners.

Among samples that included only drug users, overdose mortality rates were as high as 451.8,^{115–117} and all-cause mortality rates ranged from 277 to 1368.^{56,114,118} Among treatment-based samples, rates of drug-related deaths ranged from 309 to 2100.^{41,104,124,128–130} Among samples of HIV-positive individuals, overdose death rates were 1120 to 1390.^{119,120}

Correlates

Type of drug. Substances most commonly associated with overdose include cocaine, nonopioid analgesics (i.e., nonsteroidal anti-inflammatory drugs), and opioids—a class of drug that includes heroin, as well as prescription opioids such as morphine, methadone, codeine, and oxycodone. Some findings on how class of drug used affects overdose outcome are highlighted here.

Cocaine was one of the major drivers of overdose in the 1990s and early 2000s, especially in urban areas such as New York City.^{22,23} In a study of witnessed overdoses in New York City in the early 2000s, powdered cocaine use predicted fatality among respondents' reported last witnessed overdose.¹⁷ However, a shift toward opioids has occurred

worldwide throughout the past several years.¹³⁵

In a study of fatal overdoses in Connecticut, 77% of accidental overdose deaths from 1997 to 2007 involved opioids.⁹⁰ Opioid deaths were also more likely to involve alcohol and benzodiazepines.^{2,85,90} Several articles focused on fentanyl, an opioid receptor agonist that is used as a filler for street heroin (or laced into heroin and cocaine) and has been more frequently prescribed in recent years.^{136,137} Fentanyl is estimated to be 80 times more potent than morphine, so a small change in dosage may be fatal. Compounding this issue, many narcotic drug screens do not routinely screen for fentanyl.¹³⁸ Only 1 of the studies that included prescription medications⁶⁹ differentiated between those who experienced overdoses secondary to nonmedical use (i.e., using in larger amounts than prescribed or not prescribed for them) and had been prescribed these drugs versus those who experienced overdoses but had never been prescribed these drugs. Of the 596 respondents included in this study, 72.8% had already been prescribed in their lifetime prescription opioids, 45.5% had already been prescribed prescription tranquilizers, and 45.1% had already been prescribed prescription stimulants. None of the mortality articles included in our review had information on whether those who died because of overdoses secondary to prescription drug use had been using these drugs for therapeutic purposes.

Whether drugs are taken in pure form on their own or combination form (including mixed with alcohol) is important.^{16,77} “Polydrug” use is associated with a much higher risk of death from overdose; a study of opioid

overdoses presenting to an emergency department in Switzerland found that up to 90% of patients tested positive for multiple drugs.¹³⁹ According to the New York City Department of Health and Mental Hygiene, about 98% of overdose deaths that occur in the city involve more than 1 substance.¹⁴⁰ In addition, a review of Australian national coroner's records from 2000 to 2007 found that 72% of drug-related deaths in released prisoners involved polydrug use.¹⁴¹

For studies based on interviews about personal overdose experiences or witnessed overdoses, we cannot know with certainty exactly what type of drug or how many the person overdosed on, but rely on participant responses (e.g., Tracy et al.¹⁶). These types of studies also often have inclusion criteria such as had to have injected heroin within the past 2 months¹⁵ or had to have injected heroin or cocaine during the preceding 30 days,³⁷ which give us some indication of what drug was likely used, but it is not always specified. Some were treatment samples of specific types of drug users^{41,43} in which we generally assume for simplicity that if they were heroin injectors, they overdosed on heroin. Some studies do specify “heroin only,” for example, or differentiate between “heroin only” and “heroin and other drugs,”⁴⁹ though, again, these are often based on self-report. Others still differentiate between single drugs and combination, but are based on autopsy findings or a mix of autopsy findings and circumstances of the fatality that we can be a little more sure about.¹¹³ Most of the larger countrywide studies on mortality or trends look at overall deaths or hospitalizations, not distinguishing between type of drug (e.g., White et al.¹¹).

Setting or regional differences.

Drug overdose is not just an urban problem, even though historically more emphasis has been placed on urban areas.^{142–144} In recent years, rural areas have seen rapid increases in rates of nonmedical prescription drug use and overdose: in rural Virginia between 1997 and 2003, fatalities attributed to overdose increased by 300% (prescription opioids and benzodiazepines were more prevalent than illicit drugs).⁷⁶ In Utah, prescription opioid deaths increased fivefold during 2000 to 2009.²⁸ Furthermore, prescription drug overdose is now the leading cause of injury death in Ohio, with particularly high rates in the rural Appalachian areas of the state.⁸⁴

In addition, the setting and circumstances of a drug overdose can tell us a lot about potential outcomes. In a study of fatal overdose in New York City in 1996, deaths were more likely to occur in neighborhoods in the top decile of income inequality than in more equitable neighborhoods.¹⁴⁵ This relationship was partially explained by the level of disorder in the environment and the quality of the built environment. When compared with nonoverdose but unintentional deaths, prescription opioid overdose deaths from another study in New York City were more likely to occur in lower-income and “fragmented” neighborhoods, but when compared with heroin fatalities, they were more likely to occur in higher-income and less-fragmented neighborhoods.¹⁴⁶ One explanation for this is that higher-income neighborhoods offer a larger supply of prescription opioids through pharmacies and physicians that is not present in more disadvantaged, primarily minority neighborhoods. A study in 10 Spanish

cities from 1996 to 2003 found that male overdose deaths were more common in cities with high levels of socioeconomic inequality.¹⁴⁷

The physical settings in which users inject also matter. A Vancouver study estimated that users who injected in public places (vs those who injected in private settings) were 4.7 times more likely to experience a nonfatal overdose.¹⁹ A study by Bohnert et al. on policing and risk of overdose in New York City found that fatal overdoses were more likely to occur in secluded public places, such as abandoned buildings.²⁰ This is likely attributable to the fact that it is more difficult to find help when someone overdoses, and may be a result of fear of heavy policing in urban areas. Another study that investigated risks of heroin overdose noted injection in an “unusual place” (defined by each individual according to his or her injecting habits) as a risk factor for overdoses.²¹ One explanation presented for this phenomenon is that tolerance is based on Pavlovian conditioning of cues, and when a user of typically high tolerance injects in an unusual circumstance, they lack the cues that they usually associate with a drug’s effect, causing their tolerance to fail.¹⁴⁸

Characteristics of the user. Lastly, characteristics of the drug user are important to consider as correlates for drug overdose. One characteristic of note is gender. Men are more likely to self-report non-medical use of prescription drugs, yet more women are more often prescribed drugs prone to abuse.^{149,150} This might be because of the fact that many common forms of pain such as osteoarthritis, fibromyalgia, lower-back pain, and shoulder pain are more prevalent among

women, and women also report higher intensity of pain from these conditions.^{151,152} The US Centers for Disease Control and Prevention reported that the proportion of drug overdose deaths caused by prescription opioids was highest among women aged 45 to 54 years and among American Indian or Alaska Natives and non-Hispanic White women.¹⁵³ A study in Australia showed a 70-to-30 male-to-female ratio of non-fatal heroin overdose.¹⁴²

Another commonly studied correlate is race/ethnicity. A review of coroner case files from British Columbia from 2001 to 2005 found that First Nations individuals had higher rates of mortality from overdose.¹⁰⁸ An investigation of fatal accidental drug overdose in New York City between 1990 and 1998 found that overdose deaths were consistently higher among non-Hispanic Blacks and Hispanics compared with non-Hispanic Whites. In addition, cocaine was more common among non-Hispanic Black decedents, whereas opioids and alcohol were more common among Hispanic and non-Hispanic White decedents.²² On the other hand, rates of prescription opioid deaths are higher among non-Hispanic Whites than among respondents of other races/ethnicities.¹⁵³

Other factors associated with increased risk of nonfatal overdose found in the literature review included belonging to a lower income group while growing up, not graduating high school, being a smoker, having ever received care at a psychiatric facility, ever witnessing a family member overdose, being prescribed tranquilizers, having cocaine dependence, and injecting in the past 90 days.^{28,36,69,154}

Certain subgroups of the population are especially prone to

overdose risk, including homeless individuals, HIV-positive individuals, and recently released prisoners.^{65,120,155,156} Individuals who have recently attended substance abuse treatment or been released from incarceration are at increased risk of overdose, often because they have lost tolerance for their usual doses.^{26,157} Overdose is also significantly associated with psychiatric disorders, suicidal ideation, and attempted suicide.^{67,158} Lastly, duration of drug use and reports of previous overdose episodes are associated with overdose.^{159,160}

DISCUSSION

We systematically synthesized the peer-reviewed literature to document the global epidemiological profile of unintentional drug overdoses, and the prevalence, time trends, mortality rates, and correlates of drug overdoses. We found, first, wide variability in the lifetime prevalence of experiencing a nonfatal overdose and in mortality rates attributable to overdoses, depending on the study setting. Second, the majority of studies on longitudinal trends of overdose death rates or overdose-related hospitalization rates showed increases in overdose death rates and in overdose-related hospitalization rates across time, which have led to peaks in these rates now. In particular, an overall trend of increasing deaths from prescription opioid use and decreasing deaths from illicit drug use in the past several years has been noted across most of the literature.^{80–82,89,90,96,97,99,100} Third, with the increase in prescription opioid overdose deaths, drug overdose is no longer just an urban problem: rural areas have seen an important increase in overdose deaths. Fourth, cocaine, prescription

opioids, and heroin are the drugs most commonly associated with unintentional drug overdoses worldwide and the demographic and psychiatric correlates associated with unintentional drug overdoses are similar worldwide. However, more studies examining these correlates are needed from non-English-speaking countries.

Drug overdose is an important, yet inadequately understood, public health problem. A review of existing studies points to several key methodological issues that future studies need to address and limitations in extant studies. Methodological issues include enhancing data collection methods on unintentional fatal and nonfatal overdoses, and collecting more detailed information on drug use history, source of drug use (for prescription drugs), and demographic and psychiatric history characteristics of the individual who overdosed. For example, future studies could employ consistency check strategies to compare medical examiner information on fatal overdoses with available medical records and information from the deceased individuals’ family members.

Future data collection efforts could also include more detailed questions when interviewing individuals who report nonfatal overdoses, and check consistency of such information with hospital discharge data and information from family or other third parties (e.g., friends who witnessed the overdose episode). The field still also lacks studies in rural areas as well as longitudinal studies of population-based drug users (i.e., non-treatment samples) in multiple urban and rural areas that would provide us with comparable prevalence estimates across different contexts.

In addition, several of the selected studies did not disclose how

they defined nonfatal overdoses to study respondents,^{33,34,37} simply mentioning that they asked them if they had ever experienced or witnessed an overdose, which could be somewhat misleading and biased. On the other hand, it should be noted that, among the studies that provided information on the definition of nonfatal overdoses, the definition of nonfatal overdoses was overall extremely consistent and standardized across the reviewed studies, similar to the definition we present in the introduction of this review.^{12,14-17,36,39,40}

The marked increase in prescription opioid overdoses described in the studies reviewed is likely attributable to a rapid increase in sales of prescription opioids during the past decade; the quantity of prescription opioids sold to pharmacies, hospitals, and doctors' offices in the United States was 4 times larger in 2010 than in 1999.⁸ The increase in overdoses caused by prescription opioid use in the United States parallels the increase in the availability of prescription opioids since the early to mid-1990s in the United States.⁹⁰ As described in one of Nora Volkow's recent presentations to the US Senate:

The number of prescriptions for opioids (like hydrocodone and oxycodone products) have escalated from around 76 million in 1991 to nearly 207 million in 2013, with the United States their biggest consumer globally, accounting for almost 100 percent of the world total for hydrocodone (i.e., Vicodin) and 81 percent for oxycodone (i.e., Percocet).^{161(p.3)}

There is a need to invest in research to understand the distinct determinants of this type of overdose worldwide. Several other countries need to collect in a systematic and continuous fashion such data on sales of prescription

opioids and other prescription drugs, nonmedical use of prescription drugs, and hospitalization secondary to overdoses on prescription drugs. Moreover, there is the need for future studies to further investigate whether those who overdose while using prescription medication had been prescribed these drugs recently or in the past because only 1 of the reviewed studies included this information.⁶⁹

Finally, the sparse evidence on the environmental determinants of overdose suggest a need for research that will inform the types of environmental interventions we can use to prevent drug overdose. A combination of studies on individuals who overdose and the settings where overdoses occur will help us better tailor interventions to the types of strategies that are most likely to have a major impact on this epidemic.

Limitations of the reviewed studies are also noted. First, most studies did not collect information on the sources of drug used, which can provide insights into the ways individuals learn about and acquire drugs, and can thus inform prevention opportunities. Drugs can be acquired from family, friends, and drug dealers, but they can also be prescribed for legitimate medical reasons (in the case of prescription drugs). More studies that investigate prescribing patterns, such as the article by Logan et al. on potentially inappropriate prescriptions given in the emergency department,¹⁶² are needed. Moreover, only about a third of the mortality rate studies, half of trends studies, and one sixth of the prevalence studies stratify results by specific types of prescription drugs.

Second, it is already well established that there might be an underreporting of intentional overdoses, because when

substance users are asked whether their overdose was or was not intentional, most report it as unintentional.^{29,163,164} In our review, we focused on unintentional overdoses, but there is the possibility that some of these overdoses were truly intentional.

Third, because substance users who experience an overdose are usually polydrug users, it is very difficult to distinguish which and how many drugs were used before an overdose episode.¹⁶⁵⁻¹⁶⁸ Because of the high prevalence of multiple drugs being present in overdoses,^{11,139} it is hard to tease out the effect of one drug over another. Overall, there is a mix of how well studies differentiate, but many aim to show an overall measure of burden of this issue, not truly trying to make a causal association with any 1 type of drug.

Fourth, studies have shown that forensic toxicology laboratories are limited in the number of drugs for which they can screen and that drug levels can change postmortem.¹⁶⁵⁻¹⁶⁸ Further complicating this issue is the fact that data collected by medical examiners and coroners are usually inadequate, incomplete, and inconsistent with regard to polydrug use, estimated drug dosage (when, for instance, the individual had a legitimate prescription for at least 1 of the drugs involved in the fatal overdose episode—e.g., a legitimate opioid prescription), and patient characteristics.¹⁶⁹

Fifth, if we are to identify potential avenues to prevent drug overdose, more concerted investment needs to be made to understand the environmental drivers of overdose risk, and the individual and interpersonal mechanisms whereby environmental characteristics can increase the risk for overdose. This is

particularly important for overdose risk in rural areas, as the bulk of the literature on environmental determinants of overdose has focused on urban areas. This also has important implications for prevention and intervention strategies that need to focus on harm reduction strategies such as the availability of safe injection facilities or mobile safe injection facilities where individuals can inject preobtained drugs under the supervision of a medical doctor, such as facilities that exist in Canada and in some European countries,¹⁹ while also offering them treatment for their drug-using behavior. ■

About the Authors

Silvia S. Martins is with the Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY. Laura Sampson and Sandro Galea are with the Department of Epidemiology, Boston University School of Public Health, Boston, MA. Magdalena Cerdá is with the Department of Emergency Medicine, University of California, Davis.

Correspondence should be sent to Silvia S. Martins, MD, PhD, Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168th St, Allen Rosenfield Building, Room 509, New York, NY 10032 (e-mail: ssm2183@columbia.edu). Reprints can be ordered at <http://www.ajph.org> by clicking the "Reprints" link.

This article was accepted July 20, 2015.

Contributors

S. S. Martins and S. Galea designed the study. S. S. Martins directed L. Sampson on the literature review, and wrote the first full draft of the manuscript. L. Sampson conducted the literature review and prepared the Methods and the Results sections of the text. S. Galea critically reviewed all drafts of the article. M. Cerdá helped write the Discussion section and critically reviewed all other sections of the article.

Acknowledgments

M. Cerdá was supported by US National Institute on Drug Abuse grant DA030449. S. S. Martins was supported by US National Institute of Child and Human Development grant HD060072 and by US National Institute on Drug Abuse grant DA 037866. S. Galea was

supported by US Health and Human Services grant HITEP130003-01-00, Department of Defense grant W81XWH-07-1-0409, and grant funding from the Rockefeller Foundation. L. Sampson was supported by the Department of Defense grant W81XWH-07-1-0409.

S. S. Martins was a consultant for Purdue Pharma until December 2014 to collaborate on a manuscript on secondary analyses of National Epidemiologic Survey on Alcohol and Related Conditions data on prescription opioid dependence.

Human Participant Protection

The article is a review of already published articles and considered non-human participant research by Columbia University's institutional review board.

References

- Paulozzi LJ. Overdoses are injuries too. *Inj Prev*. 2007;13(5):293–294.
- Cerdá M, Ransome Y, Keyes KM, et al. Prescription opioid mortality trends in New York City, 1990–2006: examining the emergence of an epidemic. *Drug Alcohol Depend*. 2013;132(1-2):53–62.
- Centers for Disease Control and Prevention. Wide-Ranging Online Data for Epidemiologic Research (WONDER). 2010. Available at: <http://wonder.cdc.gov>. Accessed September 27, 2011.
- International Overdose Awareness Day. Overdose: worse than the road toll. Available at: <http://www.overdoseday.com/wp-content/uploads/2013/07/Factsheet-Greater-than-the-Road-Toll-KE-FINAL-15-August-2013.pdf>. Accessed August 14, 2015.
- 2012 annual report on the state of the drugs problem in Europe. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2012.
- Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. *MMWR Morb Mortal Wkly Rep*. 2013;62(26):537–542.
- Centers for Disease Control and Prevention. Overdose deaths involving prescription opioids among Medicaid enrollees—Washington, 2004–2007. *MMWR Morb Mortal Wkly Rep*. 2009;58(42):1171–1175.
- Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. 2011;60(43):1487–1492.
- Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson M. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. *J Urban Health*. 2007;84(2):283–291.
- Schweitzer VG, Darrat I, Stach BA, Gray E. Sudden bilateral sensorineural hearing loss following polysubstance narcotic overdose. *J Am Acad Audiol*. 2011;22(4):208–214.
- White AM, Hingson RW, Pan IJ, Yi HY. Hospitalizations for alcohol and drug overdoses in young adults ages 18–24 in the United States, 1999–2008: results from the Nationwide Inpatient Sample. *J Stud Alcohol Drugs*. 2011;72(5):774–786.
- McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. *Addiction*. 1998;93(5):701–711.
- Ochoa KC, Hahn JA, Seal KH, Moss AR. Overdosing among young injection drug users in San Francisco. *Addict Behav*. 2001;26(3):453–460.
- Bohnert AS, Tracy M, Galea S. Characteristics of drug users who witness many overdoses: implications for overdose prevention. *Drug Alcohol Depend*. 2012;120(1-3):168–173.
- Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. *Acad Emerg Med*. 2007;14(7):616–623.
- Tracy M, Piper TM, Ompad D, et al. Circumstances of witnessed drug overdose in New York City: implications for intervention. *Drug Alcohol Depend*. 2005;79(2):181–190.
- Bohnert AS, Tracy M, Galea S. Circumstances and witness characteristics associated with overdose fatality. *Ann Emerg Med*. 2009;54(4):618–624.
- Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. *MMWR Morb Mortal Wkly Rep*. 2012;61(6):101–105.
- Fairbairn N, Wood E, Stoltz JA, Li K, Montaner J, Kerr T. Crystal methamphetamine use associated with non-fatal overdose among a cohort of injection drug users in Vancouver. *Public Health*. 2008;122(1):70–78.
- Bohnert AS, Nandi A, Tracy M, et al. Policing and risk of overdose mortality in urban neighborhoods. *Drug Alcohol Depend*. 2011;113(1):62–68.
- Gutiérrez-Cebollada J, de la Torre R, Ortuño J, Garcés J, Camí J. Psychotropic drug consumption and other factors associated with heroin overdose. *Drug Alcohol Depend*. 1994;35(2):169–174.
- Galea S, Ahern J, Tardiff K, et al. Racial/ethnic disparities in overdose mortality trends in New York City, 1990–1998. *J Urban Health*. 2003;80(2):201–211.
- Zimmerman JL. Cocaine intoxication. *Crit Care Clin*. 2012;28(4):517–526.
- Vormfelde SV, Poser W. Death attributed to methadone. *Pharmacopsychiatry*. 2001;34(6):217–222.
- Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction*. 2011;106(1):32–51.
- Paulozzi LJ. Prescription drug overdoses: a review. *J Safety Res*. 2012;43(4):283–289.
- Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. *Bull World Health Organ*. 2013;91(2):102–123.
- Lamier WA, Johnson EM, Rolfs RT, Friedrichs MD, Grey TC. Risk factors for prescription opioid-related death, Utah, 2008–2009. *Pain Med*. 2012;13(12):1580–1589.
- Bohnert AS, Roeder K, Ilgen MA. Unintentional overdose and suicide among substance users: a review of overlap and risk factors. *Drug Alcohol Depend*. 2010;110(3):183–192.
- Merrall EL, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. *Addiction*. 2010;105(9):1545–1554.
- PubMed. Bethesda, MD: US National Library of Medicine, National Institutes of Health.
- Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. *Addict Behav*. 2006;31(5):907–912.
- Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. *Addiction*. 2005;100(3):397–404.
- Werb D, Kerr T, Lai C, Montaner J, Wood E. Nonfatal overdose among a cohort of street-involved youth. *J Adolesc Health*. 2008;42(3):303–306.
- Britton PC, Wines JD II, Conner KR. Non-fatal overdose in the 12 months following treatment for substance use disorders. *Drug Alcohol Depend*. 2010;107(1):51–55.
- Galea S, Nandi A, Coffin PO, et al. Heroin and cocaine dependence and the risk of accidental non-fatal drug overdose. *J Addict Dis*. 2006;25(3):79–87.
- Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. *J Subst Abuse Treat*. 2006;30(2):129–133.
- Brådvik L, Frank A, Hulénvik P, Medvedeo A, Berglund M. Heroin addicts reporting previous heroin overdoses also report suicide attempts. *Suicide Life Threat Behav*. 2007;37(4):475–481.
- Baca CT, Grant KJ. What heroin users tell us about overdose. *J Addict Dis*. 2007;26(4):63–68.
- Cullen W, Bury G, Langton D. Experience of heroin overdose among drug users attending general practice. *Br J Gen Pract*. 2000;50(456):546–549.
- Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001–2009. *Drug Alcohol Depend*. 2011;115(3):190–195.
- Darke S, Sunjic S, Zador D, Prolov T. A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. *Drug Alcohol Depend*. 1997;47(1):45–53.
- Kerr D, Dietze P, Kelly AM, Jolley D. Improved response by peers after witnessed heroin overdose in Melbourne. *Drug Alcohol Rev*. 2009;28(3):327–330.
- Kerr D, Dietze P, Kelly AM, Jolley D. Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. *J Urban Health*. 2008;85(3):352–360.
- Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: II. responses to overdose. *Addiction*. 1996;91(3):413–417.
- Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. *Addiction*. 1996;91(3):405–411.
- Gossop M, Griffiths P, Powis B, Williamson S, Strang J. Frequency of non-fatal heroin overdose: survey of heroin users recruited in non-clinical settings. *BMJ*. 1996;313(7054):402.
- Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998–1999. *Am J Public Health*. 2001;91(11):1842–1846.
- Taylor A, Frischer M, Goldberg D. Non-fatal overdosing is related to poly-drug use in Glasgow. *BMJ*. 1996;313(7069):1400–1401.
- Bluthenthal RN, Kral AH, Lorvick J, Erringer EA, Edlin BR. Harm reduction

- and needle exchange programmes. *Lancet*. 1998;351(9118):1819–1820.
51. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. *J Urban Health*. 2005;82(2):303–311.
52. Jenkins LM, Banta-Green CJ, Maynard C, et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. *J Urban Health*. 2011;88(1):118–128.
53. Sherman SG, Cheng Y, Kral AH. Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. *Drug Alcohol Depend*. 2007;88(2-3):182–187.
54. Pollini RA, McCall L, Mehta SH, Celentano DD, Vlahov D, Strathdee SA. Response to overdose among injection drug users. *Am J Prev Med*. 2006;31(3):261–264.
55. Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. *Int J Drug Policy*. 2010;21(3):186–193.
56. Evans JL, Tsui JJ, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO Study. *Am J Epidemiol*. 2012;175(4):302–308.
57. Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. *J Urban Health*. 2003;80(2):291–301.
58. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. *Addiction*. 2002;97(12):1511–1516.
59. Sergeev B, Karpets A, Sarang A, Tikhonov M. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. *J Urban Health*. 2003;80(2):212–219.
60. Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. *Addiction*. 1999;94(4):471–478.
61. Kerr T, Fairbairn N, Tyndall M, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. *Drug Alcohol Depend*. 2007;87(1):39–45.
62. Bennett GA, Higgins DS. Accidental overdose among injecting drug users in Dorset, UK. *Addiction*. 1999;94(8):1179–1189.
63. Bergstrom A, Quan VM, Van Nam L, et al. A cross-sectional study on prevalence of non-fatal drug overdose and associated risk characteristics among out-of-treatment injecting drug users in North Vietnam. *Subst Use Misuse*. 2008;43(1):73–84.
64. Havens JR, Oser CB, Knudsen HK, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. *Drug Alcohol Depend*. 2011;115(1-2):107–112.
65. Fischer B, Brissette S, Brochu S, et al. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. *CMAJ*. 2004;171(3):235–239.
66. Fischer B, Manzoni P, Rehm J. Comparing injecting and non-injecting illicit opioid users in a multisite Canadian sample (OPICAN Cohort). *Eur Addict Res*. 2006;12(4):230–239.
67. Tobin KE, Latkin CA. The relationship between depressive symptoms and nonfatal overdose among a sample of drug users in Baltimore, Maryland. *J Urban Health*. 2003;80(2):220–229.
68. Man LH, Best D, Gossop M, Stillwell G, Strang J. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. *Eur Addict Res*. 2004;10(1):35–40.
69. Silva K, Schragger SM, Kecojevic A, Lankenau SE. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. *Drug Alcohol Depend*. 2013;128(1-2):104–110.
70. Kinner SA, Milloy M, Wood E, Qi J, Zhang R, Kerr T. Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. *Addict Behav*. 2012;37(6):691–696.
71. Centers for Disease Control and Prevention. Unintentional and undetermined poisoning deaths—11 States, 1990–2001. *MMWR Morbid Mortal Wkly Rep*. 2004;53(11):233–238.
72. Paulozzi LJ, Annett JL. US data show sharply rising drug-induced death rates. *Inj Prev*. 2007;13(2):130–132.
73. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban–rural status and by drug type. *Pharmacoepidemiol Drug Saf*. 2008;17(10):997–1005.
74. Degenhardt L, Day C, Dietze P, et al. Effects of a sustained heroin shortage in three Australian States. *Addiction*. 2005;100(7):908–920.
75. Edwards EM, Searles J, Shapiro S. Deaths involving drugs in Vermont, 2004 through 2010. *Arch Intern Med*. 2011;171(18):1676–1678.
76. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. *Am J Addict*. 2009;18(1):5–14.
77. Hammersley R, Cassidy M, Oliver J, Hammersley R, Cassidy MT, Oliver J. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. *Addiction*. 1995;90(7):959–965.
78. Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. *Addiction*. 2008;103(1):126–136.
79. Mueller MR, Shah NG, Landen MG. Unintentional prescription drug overdose deaths in New Mexico, 1994–2003. *Am J Prev Med*. 2006;30(5):423–429.
80. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. *Pharmacoepidemiol Drug Saf*. 2006;15(9):618–627.
81. Fingerhut L. Increases in poisoning and methadone-related deaths: United States, 1999–2005. Centers for Disease Control and Prevention. 2008. Available at: <http://www.cdc.gov/nchs/data/hestat/poisoning/poisoning.pdf>. Accessed August 14, 2015.
82. Centers for Disease Control and Prevention. Drug overdose deaths—Florida, 2003–2009. *MMWR Morb Mortal Wkly Rep*. 2011;60(26):869–872.
83. Madden ME, Shapiro SL. The methadone epidemic: methadone-related deaths on the rise in Vermont. *Am J Forensic Med Pathol*. 2011;32(2):131–135.
84. Socie E, Hirsch A, Beeghly CB, Ohio Department of Health, Centers for Disease Control and Prevention. The Burden of Poisoning in Ohio, 1999–2008. Columbus, OH: Violence and Injury Prevention Program, Ohio Department of Health; 2010.
85. Wells C. Report: Deaths related to drug poisoning in England and Wales, 2008. *Health Stat Q*. 2009;(43):48–55.
86. Wisniewski AM, Purdy C, Blondell R. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. *J Addict Dis*. 2008;27(1):1–11.
87. Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. *MMWR Morbid Mortal Wkly Rep*. 2012;61(26):493–497.
88. Hawton K, Bergen H, Simkin S, Wells C, Kapur N, Gunnell D. Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. *PLoS Med*. 2012;9(5):e1001213.
89. *Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits*. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. HHS publication no. (SMA) 13-4760, DAWN Series D-39.
90. Green TC, Grau LE, Carver H, Kinzly M, Heimer R. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997–2007. *Drug Alcohol Depend*. 2011;115(3):221–228.
91. Degenhardt LJ, Conroy E, Gilmour S, Hall W. The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. *Med J Aust*. 2005;182(1):20–23.
92. Calcaterra S, Glanz J, Binswanger I. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. *Drug Alcohol Depend*. 2013;131(3):263–270.
93. Cochella S, Bateman K. Provider detailing: an intervention to decrease prescription opioid deaths in Utah. *Pain Med*. 2011; 12(suppl 2):S73–S76.
94. Johnson EM, Porucznik C, Anderson J, Rofls R. State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. *Pain Med*. 2011;12(suppl 2):S66–S72.
95. Scott G, Thomas SD, Pollack HA, Ray B. Observed patterns of illicit opiate overdose deaths in Chicago, 1999–2003. *J Urban Health*. 2007;84(2):292–306.
96. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet*. 2011; 377(9775):1429–1437.
97. Wood E, Stoltz JA, Li K, Montaner JS, Kerr T. Changes in Canadian heroin supply coinciding with the Australian heroin shortage. *Addiction*. 2006;101(5):689–695.
98. Friedman LS. Real-time surveillance of illicit drug overdoses using poison center data. *Clin Toxicol (Phila)*. 2009;47(6):573–579.
99. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *Am J Public Health*. 2013;103(5):917–922.
100. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. *J Addict Dis*. 2006;25(3):89–96.

101. Neeleman J, Farrell M. Fatal methadone and heroin overdoses: time trends in England and Wales. *J Epidemiol Community Health*. 1997;51(4):435–437.
102. Duncan DF. Drug law enforcement expenditures and drug-induced deaths. *Psychol Rep*. 1994;75(1 pt 1):57–58.
103. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980–2008. *NCHS Data Brief*. 2011;81(22):1–8.
104. Merrall EL, Bird SM, Hutchinson SJ. Mortality of those who attended drug services in Scotland 1996–2006: record-linkage study. *Int J Drug Policy*. 2012;23(1):24–32.
105. Shah NG, Lathrop SL, Flores JE, Landen MG. The influence of living along the U.S.–Mexico border on unintentional drug overdose death, New Mexico (USA), 2005–2009. *Drug Alcohol Depend*. 2012;125(1-2):19–26.
106. Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. *Addiction*. 2008;103(2):251–255.
107. Marshall BD, Milloy MJ, Wood E, Galea S, Kerr T. Temporal and geographic shifts in urban and non-urban cocaine-related fatal overdoses in a Canadian setting. *Ann Epidemiol*. 2012;22(3):198–206.
108. Milloy MJ, Wood E, Reading C, Kane D, Montaner J, Kerr T. Elevated overdose mortality rates among First Nations individuals in a Canadian setting: a population-based analysis. *Addiction*. 2010;105(11):1962–1970.
109. Harlow KC. Patterns of rates of mortality from narcotics and cocaine overdose in Texas, 1976–87. *Public Health Rep*. 1990;105(5):455–462.
110. Coffin PO, Galea S, Ahern K, Leon A, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. *Addiction*. 2003;98(6):739–747.
111. Torralba L, Brugal MT, Villalbi JR, Tortosa MT, Toribio A, Valverde JL. Mortality due to acute adverse drug reactions: opiates and cocaine in Barcelona, 1989–93. *Addiction*. 1996;91(3):419–426.
112. Marzuk PM, Tardiff K, Leon AC, et al. Poverty and fatal accidental drug overdoses of cocaine and opiates in New York City: an ecological study. *Am J Drug Alcohol Abuse*. 1997;23(2):221–228.
113. Tardiff K, Marzuk P, Leon A, et al. Accidental fatal drug overdoses in New York City: 1990–1992. *Am J Drug Alcohol Abuse*. 1996;22(2):135–146.
114. Stenbacka M, Leifman A, Romelsjö A. Mortality and cause of death among 1705 illicit drug users: a 37-year follow up. *Drug Alcohol Rev*. 2010;29(1):21–27.
115. Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. cities. *Subst Use Misuse*. 2008;43(3-4):413–428.
116. Hickman M, Hope V, Coleman B, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. *J Public Health (Oxf)*. 2009;31(3):374–382.
117. Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. *Coll Antropol*. 2006;30(3):479–488.
118. Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. *Harm Reduct J*. 2007;4:1.
119. Wang C, Vlahov D, Galai N, et al. The effect of HIV infection on overdose mortality. *AIDS*. 2005;19(9):935–942.
120. Brettell RP, Chiswick A, Bell J, et al. Pre-AIDS deaths in HIV infection related to intravenous drug use. *QJM*. 1997;90(10):617–629.
121. Davidson PJ, McLean R, Kral A, Gleghorn A, Edlin B, Moss A. Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. *J Urban Health*. 2003;80(2):261–273.
122. Ruttenber AJ, Luke JL. Heroin-related deaths: new epidemiologic insights. *Science*. 1984;226(4670):14–20.
123. Centers for Disease Control and Prevention. Vital signs: prescription painkiller overdoses: use and abuse of methadone as a painkiller. National Center for Injury Prevention and Control. 2012. Available at: <http://www.cdc.gov/VitalSigns/pdf/2012-07-vitalsigns.pdf>. Accessed August 14, 2015.
124. Soyka M, Apelt S, Lieb M, Wittchen H. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. *J Clin Psychopharmacol*. 2006;26(6):657–660.
125. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. *JAMA*. 2008;300(22):2613–2620.
126. Niveau G, Rougemont AL, La Harpe R. Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983–1999. *Eur J Public Health*. 2002;12(3):224–227.
127. Albert S, Brason FW II, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. *Pain Med*. 2011;12(suppl 2):S77–S85.
128. Bird SM. Over 1200 drugs-related deaths and 190,000 opiate-users-years of follow-up: relative risks by sex and age group. *Addict Res Theory*. 2010;18:194–207.
129. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. *Eur J Public Health*. 2006;16(2):198–202.
130. Clausen T, Waal H, Thoresen M, Gossop M. Mortality among opiate users: opioid maintenance therapy, age and causes of death. *Addiction*. 2009;104(8):1356–1362.
131. Shah R, Uren Z, Baker A, Majeed A. Trends in deaths from drug overdose and poisoning in England and Wales 1993–1998. *J Public Health Med*. 2001;23(3):242–246.
132. Morgan O, Griffiths C, Baker A, Majeed A. Fatal toxicity of antidepressants in England and Wales, 1993–2002. *Health Stat Q*. 2004;(23):18–24.
133. Rocchi MB, Miotto P, Preti A. Distribution of deaths by unintentional illicit drug overdose in Italy based on periodicity over time, 1984–2000. *Drug Alcohol Depend*. 2003;72(1):23–31.
134. Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005–2009. *Pharmacoepidemiol Drug Saf*. 2013;22(4):438–442.
135. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. *JAMA*. 2013;309(7):657–659.
136. Krinsky CS, Lathrop SL, Crossey M, Baker G, Zumwalt R. A toxicology-based review of fentanyl-related deaths in New Mexico (1986–2007). *Am J Forensic Med Pathol*. 2011;32(4):347–351.
137. Boddiger D. Fentanyl-laced street drugs “kill hundreds.” *Lancet*. 2006;368(9535):569–570.
138. Soloway RA. Street-smart advice on treating drug overdoses. *Am J Nurs*. 1993;93(9):65–72.
139. Cook S, Moeschler O, Michaud K, Yersin B. Acute opiate overdose: characteristics of 190 consecutive cases. *Addiction*. 1998;93(10):1559–1565.
140. New York City Department of Health and Mental Hygiene. Illicit drug use in New York City. *NYC Vital Signs*. 2010;9(1):1–4.
141. Andrews JY, Kinner SA. Understanding drug-related mortality in released prisoners: a review of national coronal records. *BMC Public Health*. 2012;12:270.
142. Clark MJ, Bates AC. Nonfatal heroin overdoses in Queensland, Australia: an analysis of ambulance data. *J Urban Health*. 2003;80(2):238–247.
143. Dietze P, Jolley D, Cvetkovski S. Patterns and characteristics of ambulance attendance at heroin overdose at a local-area level in Melbourne, Australia: implications for service provision. *J Urban Health*. 2003;80(2):248–260.
144. Degenhardt L, Hall W, Adelstein B. Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. *Aust N Z J Public Health*. 2001;25(5):447–450.
145. Nandi A, Galea S, Ahern J, Bucciarelli A, Vlahov D, Tardiff K. What explains the association between neighborhood-level income inequality and the risk of fatal overdose in New York City? *Soc Sci Med*. 2006;63(3):662–674.
146. Cerdá M, Ransome Y, Keyes KM, et al. Revisiting the role of the urban environment in substance use: the case of analgesic overdose fatalities. *Am J Public Health*. 2013;103(12):2252–2260.
147. Gotsens M, Mari-Dell’Olmo M, Martínez-Beneito MA, et al. Socio-economic inequalities in mortality due to injuries in small areas of ten cities in Spain (MEDEA Project). *Accid Anal Prev*. 2011;43(5):1802–1810.
148. Siegel S. Pavlovian conditioning and drug overdose: when tolerance fails. *Addict Res Theory*. 2001;9(5):503–513.
149. Simoni-Wastila L, Ritter G, Strickler G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. *Subst Use Misuse*. 2004;39(1):1–23.
150. Raofi S, Schappert S. Medication therapy in ambulatory medical care; United States, 2003–2004. *Vital Health Stat*. 2006;13(163):1–40.
151. Rustøen T, Wahl AK, Hanestad BR, Lerdal A, Paul S, Miaskowski C. Gender differences in chronic pain—findings from a population-based study of Norwegian adults. *Pain Manag Nurs*. 2004;5(3):105–117.
152. Hunter J, Smith B, Gribbin M. Demographic variables and chronic pain. *Clin J Pain*. 2001;17(4 suppl):S14–S19.
153. Centers for Disease Control and Prevention. Prescription painkiller overdoses: a growing epidemic, especially among women. 2013. Available at: <http://www.cdc.gov/vitalsigns/PrescriptionPainkillerOverdoses/index.html>. Accessed August 14, 2015.
154. Cheng M, Sauer B, Johnson E, Porucznik C, Hegmann K. Comparison of opioid-related deaths by work-related injury. *Am J Ind Med*. 2013;56(3):308–316.

155. Green TC, McGowan S, Yokell M, Pouget E, Rich J. HIV infection and risk of overdose: a systematic review and meta-analysis. *AIDS*. 2012;26(4):403–417.
156. Stewart LM, Henderson C, Hobbs M, Ridout S, Knuiman M. Risk of death in prisoners after release from jail. *Aust NZ J Public Health*. 2004;28(1):32–36.
157. Wines JD, Saitz R, Horton N, Lloyd-Travaglini C, Samet J. Overdose after detoxification: a prospective study. *Drug Alcohol Depend*. 2007;89(2-3):161–169.
158. Bohnert AS, Ilgen MA, Ignacio RV, McCarthy JF, Valenstein M, Blow FC. Risk of death from accidental overdose associated with psychiatric and substance use disorders. *Am J Psychiatry*. 2012; 169(1):64–70.
159. Ødegård E, Rossow I. Alcohol and non-fatal drug overdoses. *Eur Addict Res*. 2004;10(4):168–172.
160. Boyes AP. Repetition of overdose: a retrospective 5-year study. *J Adv Nurs*. 1994;20(3):462–468.
161. Volkow ND. Prescription opioid and heroin abuse: witness appearing before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations: Department of Health and Human Services, National Institutes of Health; April 29, 2014.
162. Logan J, Liu Y, Paulozzi L, Zhang K, Jones C. Opioid prescribing in emergency departments: the prevalence of potentially inappropriate prescribing and misuse. *Med Care*. 2013;51(8):646–653.
163. National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System: leading causes of death reports. 2008.
164. Shai D. Problems of accuracy in official statistics on drug-related deaths. *Int J Addict*. 1994;29(14):1801–1811.
165. Skopp G. Postmortem toxicology. *Forensic Sci Med Pathol*. 2010;6(4):314–325.
166. Pounder DJ, Fuke C, Cox DE, Smith D, Kuroda N. Postmortem diffusion of drugs from gastric residue: an experimental study. *Am J Forensic Med Pathol*. 1996;17(1):1–7.
167. Pounder DJ, Adams E, Fuke C, Langford A. Site to site variability of post-mortem drug concentration in liver and lung. *J Forensic Sci*. 1996;41(6):927–932.
168. Kostakis C, Byard R. Sudden death associated with intravenous injection of toad extract. *Forensic Sci Int*. 2009; 188(1-3):e1–e5.
169. Webster LR, Dasgupta N. Obtaining adequate data to determine causes of opioid-related overdose deaths. *Pain Med*. 2011;12(suppl 2):S86–S92.